Claims for Patent: 8,748,169

Summary for Patent: 8,748,169

Title:	Methods and compositions relating to restricted expression lentiviral vectors and their applications
Abstract:	The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise promoters active to promote expression specific to cell types or tissues. Further, promoters are providing that are amenable to control by activators, enhancers, or repressors. These vectors are in a self-inactivating configuration for biosaftey. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element, without any decrease in the specificity or control exerted by the promoters. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s):	Trono; Didier (Collonge, CH), Wiznerowicz; Maciej (Geneva, CH)
Assignee:	Research Development Foundation (Carson City, NV)
Application Number:	11/680,414
Patent Claims:	1. A recombinant lentiviral vector comprising: (a) an expression cassette comprising a transgene positioned under the control of a promoter that is active to promote detectable transcription of the transgene in a human cell, (b) a central polypurine tract (cPPT) positioned upstream of the expression cassette; and (c) multiple unique cloning sites positioned downstream, both upstream and downstream of the cPPT or between the cPPT and the promoter. 2. The vector of claim 1, wherein the cPPT comprises the nucleotide sequence of SEQ ID NO: 1. 3. The vector of claim 1, wherein the vector is capable of transducing 20% to 80% of cells. 4. The vector of claim 1, wherein the vector is capable of transducing 40% to 80% of cells. 5. The vector of claim 1, wherein the vector is capable of transducing 60% to 80% of cells. 6. The vector of claim 1, wherein the multiple unique cloning sites are positioned downstream of the cPPT. 7. The vector of claim 1, wherein multiple unique cloning sites are positioned both upstream and downstream of the cPPT. 8. The vector of claim 1, further defined as a self-inactivating vector (SIN). 9. The vector of claim 1, wherein transcription of the LTR region has been reduced by virtue of deletions in the U3 region of the 3' LTR. 10. The vector of claim 9, wherein the deletions are of nucleotides at positions -418 through -18 relative to the U3-R region boundary. 11. The vector of claim 1, further defined as incapable of reconstituting a wild-type lentivirus through recombination. 12. The vector of claim 1, wherein the promoter is a gp91-phox promoter, a gp47-phox promoter, a CD11b promoter, an EF1-.alpha. promoter, a PGK promoter, a beta-globin promoter, an MHC classII promoter, a clotting Factor IX promoter, an insulin promoter, a PDX1promoter, a CD4 promoter, and a CD2 promoter. 13. The vector of claim 12, wherein the promoter is a gp91-phox promoter. 14. The vector of claim 12, wherein the promoter is a gp47-phox promoter. 15. The vector of claim 12, wherein the promoter is a CD11b promoter. 16. The vector of claim 12, wherein the promoter is the EF1-.alpha. promoter. 17. The vector of claim 12, further comprising at least one enhancer sequence. 18. The vector of claim 17, wherein the at least one enhancer sequence is selected from the group of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. 19. The vector of claim 17, wherein the at least one enhancer sequence is positioned adjacent to the cPPT. 20. The vector of claim 17, wherein the at least one enhancer sequence is positioned upstream of the cPPT. 21. The vector of claim 17, wherein the at least one enhancer sequence is positioned downstream of the cPPT. 22. The vector of claim 17, wherein enhancer sequences are positioned both upstream and downstream of the cPPT. 23. The vector of claim 1, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 10 and about 200. 24. The vector of claim 23, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200. 25. The vector of claim 24, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200. 26. The vector of claim 1, wherein the promoter is capable of promoting expression of the transgene in response to a transcriptional activator. 27. The vector of claim 26, wherein the transcriptional activator is INF-gamma. 28. The vector of claim 26, wherein the promoter is capable of promoting expression of the transgene in specific cell types. 29. The vector of claim 1, wherein the promoter is capable of promoting expression of the transgene in specific cell types. 30. The vector of claim 29, wherein the specific cell types are selected from the group of mature blood cells, neutrophils, monocytes, granulocytes, neurons, lung cells, muscle cells, liver cells, pancreatic cells, endothelial cells, cardiac cells, skin cells, bone marrow stromal cells, and eye cells. 31. The vector of claim 29, wherein the cell types are mature blood cells. 32. The vector of claim 29, wherein the cell types are neutrophils. 33. The vector of claim 29, wherein the cell types are monocytes or granulocytes. 34. The vector of claim 29, wherein the cell types are neurons. 35. The vector of claim 1, wherein the transgene is gp91-phox, gp47-phox, erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb.beta., a multidrug resistance gene, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibody (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE, a marker gene, luciferase, or GFP. 36. The vector of claim 35, wherein the transgene is gp91-phox. 37. The vector of claim 35, wherein the transgene is gp47-phox. 38. The vector of claim 35, wherein the transgene is a gene coding for a marker gene. 39. The vector of claim 35, wherein the transgene is a gene coding for a GFP. 40. An in vitro host cell transduced with a vector in accordance with claim 1. 41. The transduced host cell of claim 40, wherein the cell is a virus producer cell. 42. The transduced host cell of claim 41, wherein the producer cell is a 293T cell. 43. The host cell of claim 42, wherein the cell is a human hematopoietic progenitor cell. 44. The transduced host cell of claim 43, wherein the human hematopoietic progenitor cell is a CD34.sup.+ cell. 45. The vector of claim 1, further comprising a posttranscriptional regulatory sequence positioned to promote the expression of the transgene. 46. The vector of claim 45, wherein the posttranscriptional regulatory sequence is an intron positioned within the expression cassette. 47. The vector of claim 46, wherein the intron is positioned in an orientation opposite the vector genomic transcript. 48. The vector of claim 45, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element. 49. The vector of claim 48, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). 50. The vector of claim 49, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE). 51. The vector of claim 1, wherein the multiple unique cloning sites are positioned between the cPPT and the promoter.

Details for Patent 8,748,169

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-10-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-10-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-10-02